News: Vendor Showcase

Sentara Study Confirms Copper - Impregnated Textiles Prevent Infections

Friday, November 30, 2018   (0 Comments)
Share |

Six Hospitals Report Lowered C. difficile, MDRO Infection Rates with Use of Cupron Linens

RICHMOND, Va. (November 27, 2018) – A  study at six Sentara hospitals in Virginia and North Carolina confirmed that the replacement of regular linens with biocidal copper-impregnated linens from Cupron – a copper-based antimicrobial technology company - significantly reduced occurrences of Clostridium difficile (C. diff) infections and infections caused by multi-drug resistant organisms (MDROs), including MRSA and VRE. The results were published in the November 2018 issue of The Journal of Hospital Infection.

“This study of Cupron’s medical textiles alone validates their effectiveness in preventing hospital acquired infections in a real world clinical setting, along with a robust infection prevention protocol,” said Jacque Butler, Director of Infection Control and Prevention at Sentara Healthcare.

The study included six Sentara hospitals: Sentara Obici Hospital, Sentara Halifax Regional Hospital, Sentara Martha Jefferson Hospital, Sentara Rockingham Medical Center, Sentara Albemarle Medical Center and Sentara Williamsburg Regional Medical Center.  Encompassing more than 1,000 beds and 175,000 patient days, it is the largest study of antimicrobial linens to date. This is the third peer-reviewed, published study of Cupron technology conducted by Sentara Healthcare. The Cupron products used in the study included copper-infused patient gowns, pillowcases, fitted and flat sheets, washcloths, bath towels, bath blankets, and thermal blankets.

The deployment of biocidal linens across the six hospitals resulted in large and statistically significant decreases in both C. diff infections and combined C. diff and MDRO infections. The study examined three time periods: one (90 days), two (180 days) and three (240 days) in comparison to baseline periods. In comparison to baseline periods, one, two, and three, there were 61 percent, 41 percent and 43 percent reductions in infections per 10,000 patient hospitalization days caused by C. diff infections, respectively; and 60 percent, 40 percent and 37 percent reductions of infections per 1,000 patient days caused by C. diff infections and MDRO infections combined.

“Patient gowns and bed linens are the most frequently touched and contaminated surfaces in patient rooms,” said Chris Andrews, CEO of Cupron. “This multi-site, linens-only trial proves that as an additional layer of protection, surrounding patients with Cupron’s copper textiles lowers infection rates and improves outcomes.”

About Cupron Medical Textiles: Cupron Medical Textiles are manufactured by Cupron, Inc. a copper-based antimicrobial technology company that harnesses the unique properties of copper for healthcare, consumer, industrial, and military applications. Cupron embeds various copper formulations in select polymers that enable finished products to deliver the desired impact. Unlike topically-applied solutions, Cupron’s durable embedded copper technology does not wash or rub off. Cupron’s patented and proprietary embedded copper technology has earned multiple, unique public health claims from the US Environmental Protection Agency (EPA).